Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Philip Karanian

Internal Medicine West Hartford, CT Medical Doctor

NPI 1437136132 CMS profile 109787

20 Isham Rd, Suite 150, West Hartford, CT 06107

Open in the dashboard

General payments

$1,776

111 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Philip Karanian of West Hartford, CT is reported in the CMS Open Payments database as having received $1,776 across 111 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22 1
2024 General $104 5
2023 General $79 4
2022 General $132 4
2021 General $128 8
2020 General $142 9
2019 General $1,169 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Philip Karanian
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Philip Karanian were reported at $22. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Philip Karanian Internal Medicine median Middle half National median
2019 $1,169 $159 $48–$570 $163
2020 $142 $119 $33–$402 $114
2021 $128 $135 $37–$521 $132
2022 $132 $141 $42–$496 $149
2023 $79 $149 $45–$519 $160
2024 $104 $154 $47–$537 $164
2025 $22 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $200 18 payments
  2. AbbVie, Inc. $181 11 payments
  3. Amgen Inc. $174 10 payments
  4. Novo Nordisk Inc $171 11 payments
  5. AstraZeneca Pharmaceuticals LP $152 9 payments
  6. Novartis Pharmaceuticals Corporation $116 8 payments
  7. Merck Sharp & Dohme Corporation $113 8 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $104 5 payments
  9. Pfizer Inc. $74 5 payments
  10. Amarin Pharma Inc. $71 4 payments
  11. Other $421 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,666 101 payments
  2. Education $110 10 payments
Products named General payments · program years 2019–2025
  1. XARELTO $189 16 payments
  2. INVOKANA $183 14 payments
  3. VRAYLAR $181 11 payments
  4. Repatha $120 7 payments
  5. ENTRESTO $116 8 payments
  6. Ozempic $113 8 payments
  7. JANUMET $94 7 payments
  8. JANUVIA $94 7 payments
  9. SPIRIVA RESPIMAT $86 4 payments
  10. JANUMET XR $79 6 payments
  11. Other $1,356 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 111 drugs

Part D claims

7,087

Median for Internal Medicine: 777

Drug cost

$683,681

Median for Internal Medicine: $73,373

Branded share of claims

19.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Januvia Sitagliptin Phosphate Brand 138 $168,926
Eliquis Apixaban Brand 115 $109,624
Ozempic Semaglutide Brand 88 $106,689
Farxiga Dapagliflozin Propanediol Brand 59 $61,206
Jardiance Empagliflozin Brand 48 $37,704
Myrbetriq Mirabegron Brand 49 $37,426
Xarelto Rivaroxaban Brand 33 $32,543
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 16 $16,976
Breo Ellipta Fluticasone/Vilanterol Brand 28 $15,777
Symbicort Budesonide/Formoterol Fumarate Brand 17 $8,083

The 10 drugs with the highest cost, of 111 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$75,289

Of which drugs: $5,226

Medicare patients

241

Average age 78

Services billed

881

125 women, 116 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 39%
Chronic kidney disease 30%
Diabetes 29%
Ischemic heart disease 29%
Atrial fibrillation 29%
Depression 29%
Heart failure 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 43 43 $3,518

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $34
$34 — —
REXULTI
  • Lundbeck LLC $25
$25 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $25
$25 16 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $20
$20 115 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

111 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record